Leysan M. Khasanova

Leysan M. Khasanova

Auto-generated profile, based on publicly available information

Leysan M. Khasanova

Scientific Centre for Expert Evaluation of Medicinal Products

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2012 in Biological Chemistry
Verified
Journal Article
Closed access
Eugene PermyakovEugene Permyakov
Eugene Permyakov
EKEkaterina L. Knyazeva
Ekaterina L. Knyazeva
LKLeysan M. Khasanova
Leysan M. Khasanova
RFRoman S. Fadeev
Roman S. Fadeev
AZAndrei P. Zhadan
Andrei P. Zhadan
EPEugene A. Permyakov
Eugene A. Permyakov
HAMLET is a complex of α-lactalbumin (α-LA) with oleic acid (OA) that selectively kills tumor cells andStreptococcus pneumoniae. To assess the contribution of the proteinaceous component to cytotoxicity of HAMLET, OA complexes with proteins structurally and functionally distinct from α-LA were prepared. Similar to HAMLET, the OA complexes with bovine β-lactoglobulin (bLG) and pike parvalbumin (pPA) (bLG-OA-45 and pPA-OA-45, respectively) inducedS. pneumoniaeD39 cell death. The activation mechanisms ofS. pneumoniaedeath for these complexes were analogous to those for HAMLET, and the cytotoxicity of the complexes increased with OA content in the preparations. The half-maximal inhibitory concentration for HEp-2 cells linearly decreased with rise in OA content in the preparations, and OA concentration in the preparations causing HEp-2 cell death was close to the cytotoxicity of OA alone. Hence, the cytotoxic action of these complexes against HEp-2 cells is induced mostly by OA. Thermal stabilization of bLG upon association with OA implies that cytotoxicity of bLG-OA-45 complex cannot be ascribed to molten globule-like conformation of the protein component. Overall, the proteinaceous component of HAMLET-like complexes studied is not a prerequisite for their activity; the cytotoxicity of these complexes is mostly due to the action of OA.

25 March 2020 in Biological Products. Prevention, Diagnosis, Treatment
Verified
Journal Article
Open access
Dmitry V. GorenkovDmitry V. Gorenkov
Dmitry V. Gorenkov
LKL. M. Khantimirova
L. M. Khantimirova
VSV. A. Shevtsov
V. A. Shevtsov
ARA. V. Rukavishnikov
A. V. Rukavishnikov
VMV. A. Merkulov
V. A. Merkulov
YOYu. V. Olefir
Yu. V. Olefir
Coronaviruses are the largest group of known positive-strand RNA viruses. Coronavirus infection can affect various animal species, as well as humans. Over the past two decades, coronaviruses have caused epidemic outbreaks of two respiratory diseases: the Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome. At the end of 2019, a new type of virus was detected in China. The virus has been spread by humantohuman transmission and has caused a viral pneumonia outbreak. The emergence of a new coronavirus proves that the diseases caused by this group of viruses pose a threat to global health due to the potential for a pandemic, and, therefore, need careful monitoring. The objective of the study was to analyse the current epidemic situation for the new coronavirus infection (COVID-19) caused by SARS-CoV-2, taking into account previous outbreaks of infections caused by MERS-CoV and SARS-CoV β-coronaviruses which pose the greatest threat to human health. The review briefly describes two epidemic outbreaks caused by SARS-CoV (2002–2004) and MERS-CoV (2012–present), summarises the current epidemic situation for the new SARS-CoV-2 coronavirus, describes the main restrictive measures undertaken to prevent the spread of infection in Russia. The paper considers aspects of potential specific therapy and the development of prophylactic vaccines against the new coronavirus infection. The review concludes that SARS-CoV-2 has pandemic potential and that new strains of β-coronaviruses are likely to cause outbreaks in the future. The paper points to the need for careful monitoring of the disease and conducting preventive anti-epidemic measures to curb the spread of infection.

15 August 2013 in Biochemistry
Verified
Journal Article
Closed access
ENEkaterina L. Nemashkalova
Ekaterina L. Nemashkalova
AKAlexei S. Kazakov
Alexei S. Kazakov
LKLeysan M. Khasanova
Leysan M. Khasanova
EPEugene A. Permyakov
Eugene A. Permyakov
Eugene PermyakovEugene Permyakov
Eugene Permyakov

26 March 2018 in Biological Products. Prevention, Diagnosis, Treatment
Verified
Journal Article
Open access
PDF file
TKT. Yu. Kozlova
T. Yu. Kozlova
LKL. M. Khantimirova
L. M. Khantimirova
ARA. V. Rukavishnikov
A. V. Rukavishnikov
VSV. A. Shevtsov
V. A. Shevtsov
В статье приведен анализ эффективности и безопасности вакцин для профилактики клещевого энцефалита (КЭ), разрешенных для применения на территории Российской Федерации. Показано, что используемые в настоящее время вакцины КЭ отечественного и зарубежного производства обеспечивают высокую иммуногенность, безопасность и эпидемиологическую эффективность в регионах с массовым охватом вакцинацией. Все зарегистрированные вакцины соответствуют основным принципам взаимозаменяемости по показаниям к применению с учетом возрастных ограничений, перечню медицинских противопоказаний, схемам вакцинации, составу вакцин, а также показателям безопасности, иммунологической активности и эффективности. Своевременные меры специфической профилактики приводят к снижению заболеваемости КЭ в эндемичных регионах.

10 March 2022 in Biological Products. Prevention, Diagnosis, Treatment
Verified
Journal Article
Open access
PDF file
ASAlexander А. Soldatov
Alexander А. Soldatov
ZAZh. I. Avdeeva
Zh. I. Avdeeva
Dmitry V. GorenkovDmitry V. Gorenkov
Dmitry V. Gorenkov
LKL. M. Khantimirova
L. M. Khantimirova
SGS. G. Guseva
S. G. Guseva
VMV. A. Merkulov
V. A. Merkulov
There are a lot of diseases known today, which are caused by genetic abnormalities. Advances in genetics and biotechnology brought about gene editing technologies that can produce almost any gene, which ultimately led to the emergence of a new class of medicines - gene therapy products (GTPs). The aim of the study was to analyse international experience in development and authorisation of GTPs. The review highlights the challenges in GTP development, related to the search for an optimal approach to therapeutic gene delivery to the target cells. Viral vectors were shown to be a promising gene delivery system, with adenovirus (AV) and adeno-associated virus (AAV) based products demonstrating the highest efficacy and safety. The paper reviews current approaches to gene editing that allow modification of AVs and AAVs to improve GTP efficacy and safety. These modifications are carried out with the aim of, e.g., including a large therapeutic gene into a viral vector, decreasing viral protein expression levels, and decreasing viral vector immunogenicity. The review summarises GTP authorisation procedures in the USA and the European Union, including data on FDA and EMA subcommittees and departments entrusted with advisory functions. The paper mentions that there is one Russian-produced GTP authorised in the Russian Federation, and some other GTPs are in the pipeline. Therefore, the Russian regulatory framework and the Eurasian regulations and recommendations should be updated in order to accommodate for GTP development and authorisation.

20 December 2018 in Biological Products. Prevention, Diagnosis, Treatment
Verified
Journal Article
Open access
PDF file
LKL. M. Khantimirova
L. M. Khantimirova
TKT. Yu. Kozlova
T. Yu. Kozlova
EPE. L. Postnova
E. L. Postnova
VSV. A. Shevtsov
V. A. Shevtsov
ARA. V. Rukavishnikov
A. V. Rukavishnikov
The article presents the results of a retrospective analysis of viral hepatitis B incidence in the Russian Federation from 2013 to 2017, taking into account the use of vaccines included into the National Immunisation Schedule and the Immunisation Programme in Case of Epidemic Outbreaks. The analysis of the data revealed a trend towards a reduction in the incidence of acute and chronic forms of hepatitis B in the territory of the Russian Federation during the past five years. The reduction of viral hepatitis B incidence was achieved thanks to a higher vaccination coverage of both children and adults. The article presents an overview of monovalent and combination recombinant hepatitis B vaccines licensed in the Russian Federation. It describes the WHO position on preventive vaccination against viral hepatitis B, and pays special attention to vaccination of people at risk. The article considers promising areas for improving immunobiological products for hepatitis B prevention, including new technologies used in vaccine production, development and introduction of new adjuvants or adjuvants systems, and development of therapeutic vaccines.